AstraZeneca US COVID-19 Vaccine Trial to Resume Upon Completion of FDA Review
By HospiMedica International staff writers Posted on 22 Oct 2020 |
Illustration
AstraZeneca Plc (Cambridgeshire, England) is set to resume its US COVID-19 vaccine trial as early as this week after the US Food and Drug Administration finishes its review of a serious illness in one of the study volunteers, according to a report by Reuters.
AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). In September, AstraZeneca had confirmed that a participant in the Phase 3 trial of the company’s experimental COVID-19 vaccine candidate developed a serious spinal inflammatory disorder called transverse myelitis, forcing it to halt the study. While regulators in the UK, Brazil, India and South Africa later allowed AstraZeneca to resume its clinical trials in those regions, the FDA had widened its investigation of the serious illness arising in the company’s COVID-19 vaccine study.
According to Reuters’ sources, the FDA is requiring the researchers conducting the trial to add information about the incident to consent forms signed by the study participants. The sources have been told that AstraZeneca’s COVID-19 vaccine trial could resume later this week, although it was unclear how the FDA would characterize the illness in the study volunteer.
Related Links:
AstraZeneca
University of Oxford
AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). In September, AstraZeneca had confirmed that a participant in the Phase 3 trial of the company’s experimental COVID-19 vaccine candidate developed a serious spinal inflammatory disorder called transverse myelitis, forcing it to halt the study. While regulators in the UK, Brazil, India and South Africa later allowed AstraZeneca to resume its clinical trials in those regions, the FDA had widened its investigation of the serious illness arising in the company’s COVID-19 vaccine study.
According to Reuters’ sources, the FDA is requiring the researchers conducting the trial to add information about the incident to consent forms signed by the study participants. The sources have been told that AstraZeneca’s COVID-19 vaccine trial could resume later this week, although it was unclear how the FDA would characterize the illness in the study volunteer.
Related Links:
AstraZeneca
University of Oxford
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans